BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 27191538)

  • 21. Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients.
    Jacobson P; Ng J; Ratanatharathorn V; Uberti J; Brundage RC
    Bone Marrow Transplant; 2001 Oct; 28(8):753-8. PubMed ID: 11781626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Precision Dosing for Tacrolimus Using Genotypes and Clinical Factors in Kidney Transplant Recipients of European Ancestry.
    Al-Kofahi M; Oetting WS; Schladt DP; Remmel RP; Guan W; Wu B; Dorr CR; Mannon RB; Matas AJ; Israni AK; Jacobson PA
    J Clin Pharmacol; 2021 Aug; 61(8):1035-1044. PubMed ID: 33512723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients.
    Zhao W; Fakhoury M; Baudouin V; Storme T; Maisin A; Deschênes G; Jacqz-Aigrain E
    Eur J Clin Pharmacol; 2013 Feb; 69(2):189-95. PubMed ID: 22706623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients.
    Lee JY; Hahn HJ; Son IJ; Suh KS; Yi NJ; Oh JM; Shin WG
    Pharmacotherapy; 2006 Aug; 26(8):1069-77. PubMed ID: 16863483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients.
    Benkali K; Prémaud A; Picard N; Rérolle JP; Toupance O; Hoizey G; Turcant A; Villemain F; Le Meur Y; Marquet P; Rousseau A
    Clin Pharmacokinet; 2009; 48(12):805-16. PubMed ID: 19902988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients.
    Han N; Yun HY; Hong JY; Kim IW; Ji E; Hong SH; Kim YS; Ha J; Shin WG; Oh JM
    Eur J Clin Pharmacol; 2013 Jan; 69(1):53-63. PubMed ID: 22660440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.
    Jacobo-Cabral CO; García-Roca P; Romero-Tejeda EM; Reyes H; Medeiros M; Castañeda-Hernández G; Trocóniz IF
    Br J Clin Pharmacol; 2015 Oct; 80(4):630-41. PubMed ID: 25846845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dosing recommendations based on population pharmacokinetics of tacrolimus in Mexican adult patients with kidney transplant.
    Reséndiz-Galván JE; Medellín-Garibay SE; Milán-Segovia RDC; Niño-Moreno PDC; Isordia-Segovia J; Romano-Moreno S
    Basic Clin Pharmacol Toxicol; 2019 Mar; 124(3):303-311. PubMed ID: 30260084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetic analysis of tacrolimus in Chinese cardiac transplant recipients.
    Gong Y; Yang M; Sun Y; Li J; Lu Y; Li X
    Eur J Hosp Pharm; 2020 Mar; 27(e1):e12-e18. PubMed ID: 32296499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.
    Zhao W; Elie V; Roussey G; Brochard K; Niaudet P; Leroy V; Loirat C; Cochat P; Cloarec S; André JL; Garaix F; Bensman A; Fakhoury M; Jacqz-Aigrain E
    Clin Pharmacol Ther; 2009 Dec; 86(6):609-18. PubMed ID: 19865079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimation of Tacrolimus Clearance in Saudi Adult Kidney Transplant Recipients.
    Alqahtani S; Alenazi M; Alsultan A; Alsarhani E
    Saudi J Kidney Dis Transpl; 2021; 32(1):101-110. PubMed ID: 34145119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation.
    Fukatsu S; Yano I; Igarashi T; Hashida T; Takayanagi K; Saito H; Uemoto S; Kiuchi T; Tanaka K; Inui K; Tanaka K; Inui K
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):479-84. PubMed ID: 11699612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients.
    Zhu J; Campagne O; Torrice CD; Flynn G; Miller JA; Patel T; Suzuki O; Ptachcinski JR; Armistead PM; Wiltshire T; Mager DE; Weiner DL; Crona DJ
    Clin Transl Sci; 2021 May; 14(3):908-918. PubMed ID: 33502111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance.
    Antignac M; Hulot JS; Boleslawski E; Hannoun L; Touitou Y; Farinotti R; Lechat P; Urien S
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):409-16. PubMed ID: 15991041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children.
    Barau C; Furlan V; Debray D; Taburet AM; Barrail-Tran A
    Br J Clin Pharmacol; 2012 Sep; 74(3):515-24. PubMed ID: 22329639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Total plasma protein effect on tacrolimus elimination in kidney transplant patients--population pharmacokinetic approach.
    Golubović B; Vučićević K; Radivojević D; Kovačević SV; Prostran M; Miljković B
    Eur J Pharm Sci; 2014 Feb; 52():34-40. PubMed ID: 24184751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients.
    Zhao W; Fakhoury M; Deschênes G; Roussey G; Brochard K; Niaudet P; Tsimaratos M; André JL; Cloarec S; Cochat P; Bensman A; Azougagh S; Jacqz-Aigrain E
    J Clin Pharmacol; 2010 Nov; 50(11):1280-91. PubMed ID: 20147615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients.
    Sam WJ; Aw M; Quak SH; Lim SM; Charles BG; Chan SY; Ho PC
    Br J Clin Pharmacol; 2000 Dec; 50(6):531-41. PubMed ID: 11136292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantation.
    Musuamba FT; Mourad M; Haufroid V; Demeyer M; Capron A; Delattre IK; Delaruelle F; Wallemacq P; Verbeeck RK
    J Clin Pharmacol; 2012 Dec; 52(12):1833-43. PubMed ID: 22207766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetics and dosage optimization of tacrolimus in pediatric patients with nephrotic syndrome
.
    Wang X; Han Y; Chen C; Ma L; Xiao H; Zhou Y; Cui Y; Wang F; Su B; Yao Y; Ding J
    Int J Clin Pharmacol Ther; 2019 Mar; 57(3):125-134. PubMed ID: 30663980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.